Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group
Research output: Contribution to journal › Article › peer-review
152Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial'. Together they form a unique fingerprint.